ANDA 208017, held by Spectra Mdcl Devices. Lidocaine Hydrochloride.
As of Nov 16, 2026, ANDA 208017 (Lidocaine Hydrochloride), held by Spectra Mdcl Devices, was first approved by FDA on Apr 18, 2018, with 0 approved supplements and 0 published complete response letters.
INDICATION AND USAGE: Lidocaine Hydrochloride Injection, USP is indicated for production of local or regional anesthesia by infiltration techniques such as percutaneous injection and intravenous regional anesthesia by peripheral nerve block techniques such as brachial plexus and intercostal and by central neural techniques such as lumbar and caudal epidural blocks, when the accepted procedures for these techniques as described in standard textbooks are observed.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Apr 18, 2018 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Lidocaine Hydrochloride1% · injectable;injection | Lidocaine Hydrochloride | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters